This double-blind active-placebo controlled trial (n=233) tested the effect of a single dose of psilocybin (25/10/1mg) with supportive therapy for treatment-resistant depression. The primary endpoint at three weeks finds a significant reduction in depressive symptoms (MADRS, 12-point drop from baseline of 32) that was significantly greater in the 25mg group vs the 1mg (placebo) group (6.6 points larger drop). The response (>50% drop in MADRS score) in the 25mg group dropped from 37% at 3 weeks to 20% at 12 weeks.
- Published
- Journal
- New England Journal of Medicine
- Authors
- Aaronson, S. T., Alvarez, O., Arden, K., Baker, A., Bennett, J. C., Bird, C., Blom, J. D., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R. L., Cattell, J. P., Daniel, A., Debattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M. K., Goodwin, G. M., Haumann, H. M., Hellerstein, D. J., Hoppe, A. I., Husain, M. I., Jelen, L. A., Kamphuis, J., Kawasaki, J., Kelly, J. R., Key, R. E., Kishon, R., Knight, G., Koolen, M. H. B., Lean, M., Licht, R. W., Malievskaia, E., Maples-Keller, J. L., Mars, J., Marwood, L., McElhiney, M. C., Miller, T. L., Mirow, A., Mistry, S., Mletzko-Crowe, T., Modlin, N. L., Nielsen, R. E., Nielson, E. M., O’Keane, V., Offerhaus, S. R., Páleníček, T., Peck, S. K., Printz, D., Rademaker, M. C., Reinholdt, F., Repantis, D., Rucker, J., Rudow, S., Ruffell, S. G. D., Rush, A. J., Schoevers, R. A., Seynaeve, M., Shao, S., Soares, J. C. K., Somers, M., Stansfield, S., Sterling, D., Strockis, A., Tsai, J., van Reemst, A., Visser, L., Wahba, M., Williams, S., Young, A. H., Ywemba, P., Zisook, S.